{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-016892","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.900707+00:00","generated_at":"2026-06-15T08:02:36.175575+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cumberland Pharma Q1 net revenue $9.2M, adj. EPS $0.11; expects Caldolor Medicare boost under NOPAIN Act","bullets":["Q1 2023 net revenues of $9.2M; net income of $0.2M ($0.01 EPS); adjusted earnings of $1.7M ($0.11 EPS).","Product revenue: Kristalose $4.3M, Sancuso $1.9M, Vibativ $1.8M, Caldolor $0.9M.","Caldolor expected to qualify for separate Medicare reimbursement under the NOPAIN Act, enacted April 2023.","FDA granted barrier-to-innovation waiver, refunding nearly $2M in RediTrex prescription drug program fees.","Balance sheet: $89M assets, $16M cash, $53M liabilities (including $16M drawn on revolver), $36M equity."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-016892","json":"https://secwatch.observer/filing/0001628280-23-016892.json","markdown":"https://secwatch.observer/filing/0001628280-23-016892.md","text":"https://secwatch.observer/filing/0001628280-23-016892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023016892/0001628280-23-016892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023016892/cpix-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:02:36.175575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66a600e608ed5d3d99a10065e3881b517d4c0b6d","claim":"CUMBERLAND PHARMACEUTICALS INC reported the first quarter of 2023 results: revenue $9.2 million, net income $0.2 million or $0.01 a share, EPS $0.01 a share.","evidence_excerpt":"Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update NASHVILLE, TENNESSEE (Tuesday, May 9, 2023) - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, today announced that the Company’s product portfolio of FDA-approved brands delivered combined revenues of $9.2 million during the first quarter of 2023. Net income for the period was $0.2 million, or $0.01 a share, resulting in adjusted earnings of $1.7 million, or $0.11 a share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023016892/0001628280-23-016892-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Revenue","value":"$9.2 million"},{"label":"Net income","value":"$0.2 million or $0.01 a share"},{"label":"EPS","value":"$0.01 a share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}